Gene · 1859
Papers3,825
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,825
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DYRK1A Signaling in the Brain: Molecular Mechanisms and Neurotransmitter Regulation. | Curr Neurovasc Res | 2026 | 42405393 | PubTator, text mining | PubMed |
| PBAE nanoparticle-mediated delivery of ASCL1 and NGN2 genes for astroglia-to-neuron reprogramming to remodel glial scar for spinal cord injury repair. | Stem Cell Res Ther | 2026 | 42401982 | PubTator, text mining | PubMed |
| Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells. | Dis Model Mech | 2026 | 42367034 | PubTator, text mining | PubMed |
| An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present). | Expert Opin Ther Pat | 2026 | 42334856 | PubTator, text mining | PubMed |
| Biological and pathogenic roles of major genes harbored in intrachromosomal amplification of chromosome 21 in childhood acute lymphoblastic leukemia (Review). | Oncol Lett | 2026 | 42290672 | PubTator, text mining | PubMed |
| Small-molecule inhibitors of the protein kinase DYRK as potential therapeutic candidates in cancer. | Cell Chem Biol | 2026 | 42269611 | PubTator, text mining | PubMed |
| Episignature leads to diagnosis and reclassification of DYRK1A variant in a child with syndromic neurodevelopmental disorder: a case report. | Front Genet | 2026 | 42256340 | PubTator, text mining | PubMed |
| SUMO3/RUNX1/AIRE/RCAN1 and DNMT3L/DYRK1A/Let-7c-5p/VEGF axes: immune dysregulation and genetic susceptibility as pulmonary risk factors in Down syndrome. | 3 Biotech | 2026 | 42245386 | PubTator, text mining | PubMed |
| The enigmatic role of tumor dormancy cells in gynecologic cancers. | Front Immunol | 2026 | 42220495 | PubTator, text mining | PubMed |
| Orchestrating mitochondrial protein import: The emerging role of DYRK1A in health and disease. | Protein Sci | 2026 | 42183629 | PubTator, text mining | PubMed |
| Identification of novel CLK1 inhibitors by computational fragment-based ligand design, co-crystallization, chemical synthesis and structure activity relationships. | Eur J Med Chem | 2026 | 42176653 | PubTator, text mining | PubMed |
| Identification of a novel oral potential multiple agonist for obesity treatment: multi-target in silico study. | J Comput Aided Mol Des | 2026 | 42162325 | PubTator, text mining | PubMed |
| Emerging role of DYRK1A as a target in cardiovascular diseases (Review). | Mol Med Rep | 2026 | 42138187 | PubTator, text mining | PubMed |
| Human and mouse regenerative macrophages enhance beta cell survival, function, and proliferation. | Islets | 2026 | 42070103 | PubTator, text mining | PubMed |
| The FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycle. | Elife | 2026 | 42059432 | PubTator, text mining | PubMed |
| A Polypharmacology-Driven Approach to Alzheimer's Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3β/FYN-α/DYRK1A) Inhibitors. | J Med Chem | 2026 | 42054438 | PubTator, text mining | PubMed |
| Enhanced antibiotic degradation in micro-nanobubble-assisted dielectric barrier discharge systems: The role of gas-liquid interfaces in ROS exposure. | J Hazard Mater | 2026 | 42025070 | PubTator, text mining | PubMed |
| DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation. | J Clin Invest | 2026 | 42024470 | PubTator, text mining | PubMed |
| Multi-Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns. | Med Res Rev | 2026 | 42001306 | PubTator, text mining | PubMed |
| Machine Learning-Driven Ensemble Screening of Multitarget Kinase Inhibitors for Tauopathy-Associated Neurodegeneration Using All-Atom and Steered MD Simulations. | ACS Chem Neurosci | 2026 | 41995061 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1859/papers?page=2